Comprehensive treatment of recurrent ovarian cancer. Clinical case
Article Sidebar
Main Article Content
Abstract
This clinical case represents a medical hіstory of a 47-year-old patient S., who consulted an oncologist with complaints of abdominal enlargement and general weakness. The ovarian cancer FIGO stage IVB (metastases to the omentum, liver, spleen, and peritoneal carcinomatosis) was diagnosed. The patient underwent multiple stages of combined treatment, including surgery, adjuvant and anti-relapse chemotherapy, hormone therapy, and intraperitoneal heat therapy (HIPEC). The case demonstrates the complexity of managing recurrent ovarian cancer, the importance of a personalized approach, and monitoring side effects to ensure quality of life.
Article Details
Copyright (c) 2025 Iryna H, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Archives of Case Reports is committed in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. In order to use the Open Access paradigm to the maximum extent in true terms as free of charge online access along with usage right, we grant usage rights through the use of specific Creative Commons license.
License: Copyright © 2017 - 2025 | 
Open Access by Archives of Case Reports is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at Heighten Science Publications Inc.
With this license, the authors are allowed that after publishing with the journal, they can share their research by posting a free draft copy of their article to any repository or website.
Compliance 'CC BY' license helps in:
| Permission to read and download | ✓ |
| Permission to display in a repository | ✓ |
| Permission to translate | ✓ |
| Commercial uses of manuscript | ✓ |
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. Available from: https://doi.org/10.3322/caac.21660
2. Matei D, Brown J, Frazier L. Advances in molecular profiling and targeted therapies in ovarian cancer. Curr Oncol Rep. 2019;21(8):71.
3. Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov21): a double blind, randomised, placebo controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–84. Available from: https://doi.org/10.1016/S1470-2045(17)30469-2
4. Borella F, Fucina S, Mangherini L, Cosma S, Carosso AR, Cusato J, et al. Hormone receptors and epithelial ovarian cancer: recent advances in biology and treatment options. Biomedicines. 2023;11(8):2157. Available from: https://doi.org/10.3390/biomedicines11082157
5. Kato S, McFall T, Takahashi K, Bamel K, Ikeda S, Eskander RN, et al. KRAS mutated, estrogen receptor positive low grade serous ovarian cancer: unraveling an exceptional response mystery. Oncologist. 2021;26(4):e530–e536. Available from: https://doi.org/10.1002/onco.13702
6. Zhu C, Guan X, Zhang X, Luan X, Song Z, Cheng X, et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer. 2022;21(1):159. Available from: https://doi.org/10.1186/s12943-022-01629-2
7. U.S. Food and Drug Administration… FDA grants accelerated approval to the combination of avutometinib and defactinib for KRAS mutated recurrent low grade serous ovarian cancer. FDA. May 8, 2025. Available from: FDA grants accelerated approval… en.wikipedia.org+3pharmacytimes.com+3ascopost.com+3reuters.com+15fda.gov+15ons.org+15
8. Beliak V, Bilobryvka R, Slipetsky R, Yakubets O, Volodko N. NCCN distress thermometer as a screening tool for detecting psychoemotional disorders in patients with malignant tumors of the female reproductive system. Proc Shevchenko Sci Soc Med Sci. 2024;73(1). Available from: https://doi.org/10.25040/ntsh2024.01.14